TÜBINGEN, Germany/BOSTON, United States – August 15, 2024 – CureVac N. V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company introducing a new generation of transformative messenger ribonucleic acid (“mRNA”) based medicines, announced the start of Part B dose confirmation of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac’s first investigational cancer vaccine based on its patented second-generation mRNA structure. It encodes a unique fusion protein comprising 8 epitopes with immunogenicity demonstrated in glioblastoma.
“After the successful finishing touch of Part A of the dose escalation of this clinical study with CVGBM, Part B of the dose escalation is to verify that we have chosen the appropriate dose based on protection and immunogenicity for further studies in patients suffering from glioblastoma,” said Dr. S. Kelly. Myriam Mendila, Scientific Director of CureVac. ” Importantly, the Data Safety Monitoring Board’s review showed that to date there have been no dose-limiting toxicities in Part A with the four doses tested, and allowed us to move on to the next part of the study. “
The first insights into dose escalation, A, will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) Congress on 13 September 2024.
For more information, please refer to the Company’s reports and filings with the United States Securities and Exchange Commission (SEC). You can download those documents by visiting EDGAR at the SEC in www. sec. gov.